Oculis Holding AG OCS
NASDAQ OCS
$12.17 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Oculis Holding AG (OCS) Share-based Compensation (2022 - 2026)

Oculis Holding AG (OCS) posted quarterly Share-based Compensation of $6.4 million for Q1 2026, up 118.32% year-over-year from $2.9 million in Q1 2025, and up 18.37% quarter-over-quarter from $5.4 million in Q4 2025.

Analysis

Oculis Holding AG (OCS) Share-based Compensation (2022 - 2026) Analysis & Trends

Oculis Holding AG's Share-based Compensation history runs 5 years deep, the most recent figure standing at $6.4 million for Q1 2026.

  • In Q1 2026, Share-based Compensation rose 118.32% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $23.0 million (up 80.81% YoY), while the FY2025 annual figure was $19.4 million, up 74.03% from the prior year.
  • Share-based Compensation for Q1 2026 stood at $6.4 million, up from $5.4 million in the prior quarter.
  • The five-year high for Share-based Compensation was $6.4 million in Q1 2026, with the low at $150513.2 in Q4 2022.
  • The 5-year median for Share-based Compensation is $2.9 million (2024), against an average of $2.8 million.
  • The sharpest annual moves came in 2024 and 2025: Share-based Compensation surged 733.86% in 2024, then soared 50.32% in 2025.
  • Oculis Holding AG's Share-based Compensation stood at $150513.2 in 2022, then surged by 680.47% to $1.2 million in 2023, then soared by 176.17% to $3.2 million in 2024, then jumped by 66.3% to $5.4 million in 2025, then climbed by 18.37% to $6.4 million in 2026.
  • Business Quant data shows OCS's Share-based Compensation at $6.4 million in Q1 2026, $5.4 million in Q4 2025, and $5.7 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 108.10 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 243.00 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 120.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 277.20 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 137.41 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 86.63 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 41.25 Mn
10 Oculis Holding AG 634.75 Mn 345.87 Mn - -6.38 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -6.38 Mn
Mar 31, 2026 6.39 Mn
Dec 31, 2025 -14.82 Mn
Sep 30, 2025 14.74 Mn
Jun 30, 2025 -3.24 Mn
Mar 31, 2025 2.93 Mn
Dec 31, 2024 -8.03 Mn
Sep 30, 2024 2.89 Mn
Jun 30, 2024 3.65 Mn
Mar 31, 2024 1.31 Mn
Dec 31, 2023 -2.93 Mn
Sep 30, 2023 1.36 Mn
Jun 30, 2023 1.36 Mn
Mar 31, 2023 156,768.57
Dec 31, 2022 150,513.18
Sep 30, 2022 200,878.59